

# HISTONE METHYLTRANSFERASES: GLOBAL MARKETS FOR RESEARCH TOOLS, DIAGNOSTICS AND DRUG DISCOVERY



**PHM128A**  
**March 2013**

Marianna Tcherpakov  
***Project Analyst***

ISBN: 1-56965-138-8

**bcc** | Research  
Market Forecasting

**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481**  
**866-285-7215, 781-489-7301**  
**www.bccresearch.com**  
**Custom Reports:**  
**carol.laverty@bccresearch.com**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE AND FORMAT	3
METHODOLOGY AND INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 INTRODUCTION TO HISTONE METHYLTRANSFERASES RESEARCH AND PRODUCT DEVELOPMENT	10
OVERVIEW	10
DNA METHYLATION	12
DNA METHYLTRANSFERASES	13
DNA METHYLATION DETECTION TECHNIQUES	14
HISTONE MODIFICATIONS	15
<i>TABLE 1 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES</i>	15
<i>TABLE 2 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES</i>	16
CHROMATIN METHYLATION REACTION	17
<i>FIGURE 1 SCHEMATIC PRESENTATION OF METHYLATION REACTION</i>	17
HISTONE METHYLTRANSFERASES: LYSINE METHYLATION	18
<i>TABLE 3 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITS FUNCTIONAL OUTCOMES</i>	19
Role of Lysine Methylation in Chromatin Transcription	20
HISTONE METHYLTRANSFERASES: ARGENINE METHYLATION	20
<i>TABLE 4 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITS FUNCTIONAL OUTCOMES</i>	22
Role of Arginine Methylation in Chromatin Transcription	22
PRDM FAMILY AND HISTONE METHYLTRANSFERASE ACTIVITY	23
<i>TABLE 5 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITY AND BINDING PARTNERS</i>	24
<i>TABLE 6 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENT PATHOLOGIES</i>	25
CHAPTER 4 DEVELOPMENT OF RESEARCH TOOLS AND REAGENTS FOR HISTONE METHYLTRANSFERASES STUDIES AND PRODUCT DEVELOPMENT	27
OVERVIEW	27

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 7 PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOR EPIGENETIC RESEARCH (%)</i>	28
<i>TABLE 8 SELECT SUPPLIERS OF EPIGENETIC PRODUCTS</i>	29
REAGENTS AND ASSAYS REQUIRED FOR HISTONE METHYLTRANSFERASES (HMT) STUDIES	30
<i>TABLE 9 PRODUCT CATEGORIES FOR HMT RESEARCH, COMPANIES MARKETING THE PRODUCTS AND AVERAGE PRICES</i>	32
ANTIBODIES FOR HMT RESEARCH	32
<i>TABLE 10 GLOBAL MARKET FOR ANTIBODIES BY INDUSTRY SEGMENT, THROUGH 2016 (\$ BILLIONS)</i>	33
<i>TABLE 11 DISTRIBUTION OF VARIOUS APPLICATIONS FOR ANTIBODIES AS A RESEARCH TOOL (%)</i>	33
<i>TABLE 12 MAIN MARKET PARTICIPANTS IN RESEARCH ANTIBODY SEGMENT AND THEIR RELATIVE MARKET SHARES (%)</i>	34
<i>TABLE 13 SOURCES OF ANTIBODIES SUPPLY FOR RESEARCH AND THEIR PERCENTAGE ON THE MARKET</i>	35
PRODUCTION OF PROTEIN AND ENZYMES FOR HMT RESEARCH	36
<i>TABLE 14 PERCENTAGE USE OF SPECIFIC PROTEIN EXPRESSION TECHNIQUES (%)</i>	37
<i>TABLE 15 GLOBAL MARKET FOR PROTEIN CHROMATOGRAPHY, THROUGH 2016 (\$ MILLIONS)</i>	38
<i>TABLE 16 AVERAGE SPENDING PER SCIENTIST ON PURIFICATION AND SEPARATION PRODUCTS (%)</i>	39
<i>TABLE 17 GLOBAL MARKET SHARES OF RECOMBINANT ENZYME MARKET BY DIFFERENT TYPE OF ENZYME IN 2012 (%)</i>	40
<i>TABLE 18 GLOBAL RECOMBINANT ENZYME MARKET SHARES BY CUSTOMER (%)</i>	41
<i>TABLE 19 LIST OF LYSINE HISTONE METHYLTRANSFERASES (KMT) AND THEIR SUBSTRATES</i>	41
<i>TABLE 20 LIST OF LYSINE HISTONE DEMETHYLASES (KDM) AND THEIR SUBSTRATES</i>	43
<i>TABLE 21 LIST OF ARGININE HISTONE METHYLTRANSFERASES AND THEIR SUBSTRATES</i>	44
MODULATORS AND INHIBITORS FOR HMT STUDIES	45
<i>TABLE 22 LIST OF INHIBITORS USED IN HISTONE METHYLTRANSFERASE RESEARCH AND PRODUCT DEVELOPMENT</i>	46
SUBSTRATES USED IN HMTS ASSAYS	47
<i>TABLE 23 SUBSTRATES FOR HMTS FOR IN VITRO STUDIES AND PERCENTAGE OF THEIR USE (%)</i>	47
IN VITRO ASSAY DEVELOPMENT MARKET FOR HMTS	48
<i>TABLE 24 SELECT IN VITRO ASSAY AND COMMERCIAL KIT PROVIDERS</i>	49
<i>FIGURE 2 SCHEMATIC REPRESENTATION OF HMTS ASSAY DEVELOPMENT</i>	49
<i>TABLE 25 LIST OF DIFFERENT ASSAY SET-UPS FOR HMT ACTIVITY MEASUREMENTS</i>	51
Selected Market Participants in Assay Development for HMT Activity	52
Perkin Elmer	52
G Bioscience	53
Epigentek	54
Cayman Chemical	54
BPS Bioscience	54

<b>TOPIC</b>	<b>PAGE NO.</b>
Reaction Biology	55
BellBrook Labs	55
Abcam	55
CisBio Bioassays	55
<i>TABLE 26 SURVEY OF SCIENTISTS' OPINIONS ABOUT EPIGENETICS SCREENING IN DRUG DISCOVERY (%)</i>	57
<i>TABLE 27 STUDIES AND ASSAY DEVELOPMENT IN SPECIFIC DISEASE AREAS (%)</i>	57
Active Motif	58
Biocius	59
BPS Bioscience	59
Cayman Chemical	60
EMD Millipore	60
Epigentek	61
Life Technologies	61
Perkin Elmer	61
Reaction Biology	62
<i>TABLE 28 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, THROUGH 2018 (\$ MILLIONS)</i>	63
<i>FIGURE 3 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, 2011-2018 (\$ MILLIONS)</i>	63
CHAPTER 5 HISTONE METHYLTRANSFERASES IN DRUG DISCOVERY AND THERAPEUTICS DEVELOPMENT	65
OVERVIEW	65
<i>TABLE 29 ALTERED HISTONE MODIFICATIONS IN DIFFERENT PATHOLOGICAL CONDITIONS</i>	65
<i>TABLE 30 CURRENT APPROVED EPIGENETIC DRUGS ON THE MARKET</i>	66
ZOLINZA	66
<i>TABLE 31 SALES OF ZOLINZA, 2008-2010, (\$ MILLIONS)</i>	67
ISTODAX	67
<i>TABLE 32 SALES OF ISTODAX, 2011 AND 2012 (\$ MILLIONS)</i>	68
VIDAZA	68
<i>TABLE 33 SALES OF VIDAZA, 2010-2012 (\$ MILLIONS)</i>	69
DACOGEN	69
<i>TABLE 34 SALES OF DACOGEN, 2009-2011 (\$ MILLIONS)</i>	70
<i>TABLE 35 EXAMPLES OF EPIGENETIC DRUG DISCOVERY PROGRAMS</i>	71
MARKET PARTICIPANTS IN THE HMT DRUG DISCOVERY SECTOR	73
CELLCENTRIC	73
CELLZOME (GSK)	76
CONSTELLATION PHARMACEUTICALS	77
DOMAINEX	78
EPITHERAPEUTICS APS	79
EPIZYME	80
<i>TABLE 36 COMPANIES DEVELOPING THERAPEUTICS WITH HISTONE METHYLTRANSFERASE AS A DRUG DISCOVERY TARGET</i>	82
CURRENT DRUG CANDIDATES AND HMT INHIBITORS IN DEVELOPMENT	83

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 37 RECENT DRUG DISCOVERY DEVELOPMENTS FOR HISTONE METHYLTRANSFERASE INHIBITORS</i>	84
G9A AND GLP INHIBITORS	85
DOT1L INHIBITORS	86
SMYD2 INHIBITORS	88
EZH2 INHIBITORS	89
SET7/9 INHIBITORS	91
INHIBITORS FOR PRMT4	93
ADDITIONAL HMTS AS DRUG DISCOVERY TARGETS	94
Nsd 2/WHSC1	94
MLL	94
Set8	95
Suv39H1	95
<i>TABLE 38 POTENTIAL MARKETS FOR HMTS DRUG DISCOVERY (\$ BILLIONS)</i>	96
DEALS IN THE EPIGENETICS SECTOR AS INDICATORS FOR MARKET DEVELOPMENT AND ACTIVITY	96
<i>TABLE 39 DEALS IN EPIGENETICS MARKET IN THE LAST DECADE</i>	96
<i>TABLE 40 YEAR AND FUNDING AMOUNT FOR EPIGENETIC COMPANIES IN HMT DRUG DISCOVERY</i>	102
<i>TABLE 41 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, THROUGH 2018 (\$ MILLIONS)</i>	103
<i>FIGURE 4 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, 2011-2018 (\$ MILLIONS)</i>	103
ADDITIONAL DRUG DISCOVERY TARGETS RELATED TO HMT RESEARCH	103
<i>TABLE 42 POTENTIAL EPIGENETICS TARGETS FOR DRUG DISCOVERY: EPIGENETIC ENZYMES CLASSES IMPORTANT IN COVALENT MODIFICATION OF DNA OR HISTONES</i>	103
HISTONE DEMETHYLASES AS DRUG TARGETS AND THEIR IMPACT ON HMT ACTIVITY	104
<i>TABLE 43 RELATIONSHIP BETWEEN DEMETHYLASES, METHYLTRANSFERASES AND THEIR RESPECTIVE HISTONE METHYLATION SITES</i>	108
CHROMATIN READERS AS DRUG TARGETS AND THEIR IMPACT ON HMT ACTIVITY	108
<i>TABLE 44 RELATIONSHIP BETWEEN HISTONE METHYLATION, METHYL READERS AND THEIR FUNCTIONS</i>	109
CHAPTER 6 HISTONE METHYLTRANSFERASES IN DIAGNOSTICS AND BIOMARKER DEVELOPMENT	114
OVERVIEW	114
<i>TABLE 45 NUMBER OF PUBMED PUBLICATIONS ON BIOMARKERS USING DIFFERENT EPIGENETIC MECHANISMS, 2012</i>	114
<i>TABLE 46 DNA METHYLATION EVENTS AND THEIR RELATION TO DIFFERENT PATHOLOGIES</i>	115
<i>TABLE 47 NUMBER OF PUBLICATIONS IN HISTONE METHYLATION AREA BASED ON DIFFERENT SEARCH CRITERIA</i>	118
<i>TABLE 48 RELATIONSHIP BETWEEN HISTONE METHYLATION AND CANCER PROGNOSIS</i>	119
LUNG CANCER AND HISTONE MODIFICATIONS	120
PROSTATE CANCER AND HISTONE MODIFICATIONS	120
BREAST CANCER AND HISTONE MODIFICATIONS	121

<b>TOPIC</b>	<b>PAGE NO.</b>
LEUKEMIA AND HISTONE MODIFICATIONS	121
ESOPHAGEAL AND GASTRIC CANCERS AND HISTONE MODIFICATIONS	121
HISTONE MODIFICATIONS IN KIDNEY, LIVER AND PANCREATIC CANCERS	122
<i>TABLE 49 DIFFERENT HISTONE METHYLTRANSFERASES AND THEIR ASSOCIATION TO CANCER DEVELOPMENT</i>	124
<i>TABLE 50 DEMETHYLASES AND THEIR ASSOCIATIONS WITH CANCER DEVELOPMENT</i>	127
<i>TABLE 51 GLOBAL BIOMARKERS MARKET, THROUGH 2015 (\$ BILLIONS)</i>	129
MARKET PARTICIPANTS IN EPIGENETIC DIAGNOSTICS SPACE	129
<i>TABLE 52 SELECT EPIGENETICS DIAGNOSTICS COMPANIES</i>	129
DIAGENODE	131
EPIGENOMICS AG	131
EPIONTIS	133
EXACT SCIENCES	134
MDXHEALTH (FORMERLY ONCOMETHYLOME SCIENCES)	134
ORION GENOMICS	135
OXFORD BIODYNAMICS	136
PROGNOSDX	137
RIBOMED BIOTECHNOLOGIES	138
SEQUENOM	139
VOLITIONRX	140
<i>TABLE 53 EXAMPLES OF AVERAGE REVENUES IN EPIGENETIC DIAGNOSTICS COMPANIES</i>	141
<i>TABLE 54 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	143
<i>FIGURE 5 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, 2011-2018 (\$ MILLIONS)</i>	143
<i>TABLE 55 DIAGNOSTICS MARKET VALUES IN ONCOLOGY SECTOR, 2013 (\$ BILLIONS)</i>	144
CHAPTER 7 IMPORTANCE OF PATENTS IN HISTONE METHYLTRANSFERASE RESEARCH AND PRODUCT DEVELOPMENT	146
<i>TABLE 56 WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH IN HISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS (NO. OF PATENTS)</i>	146
<i>TABLE 57 WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENT APPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDING TO ASSIGNEE</i>	148
CHAPTER 8 MARKET SUMMARY	150
<i>TABLE 58 NUMBER OF PUBLICATIONS USING HISTONE METHYLTRANSFERASE AS SEARCH, 2000-2012</i>	150
<i>FIGURE 6 NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONE METHYLTRANSFERASE AS SEARCH</i>	150
<i>TABLE 59 DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS IN EPIGENETIC SPACE (%)</i>	151
<i>TABLE 60 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	152
<i>FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)</i>	153

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 61 EXAMPLES OF MARKET PARTICIPANTS IN HISTONE METHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS</i>	153
<b>CHAPTER 9 PROFILES OF SELECT COMPANIES</b>	156
CELLCENTRIC LTD.	156
CONSTELLATION PHARMACEUTICALS	157
DOMAINEX	158
EPITHERAPEUTICS APS	160
EPIZYME, INC.	161
EISAI CO., LTD.	162
GLAXOSMITHKLINE (GSK)	163
<b>CHAPTER 10 LIST OF COMPANIES MENTIONED IN REPORT</b>	167
ABCAM	167
ACTIVE MOTIF	167
ANASPEC	167
BELLBROOK LABS	167
BOEHRINGER INGELHEIM GMBH	167
CAYMAN CHEMICAL COMPANY	167
CELGENE CORPORATION	168
CELLCENTRIC LTD.	168
CELL SIGNALING TECHNOLOGY, INC.	168
CISBIO US	168
CONSTELLATION PHARMACEUTICALS	168
DIAGENODE INC. USA	168
DOMAINEX	169
EISAI CO., LTD.	169
EMD GROUP (EMD MILLIPORE)	169
ENZO LIFE SCIENCES, INC.	169
EPIGENOMICS AG	169
EPIGENTEK GROUP INC.	169
EPITHERAPEUTICS APS	170
EPIZYME, INC.	170
EXACT SCIENCES CORPORATION	170
G-BIOSCIENCES	170
GSK US	170
JOHNSON & JOHNSON	170
LIFE TECHNOLOGIES CORP.	171
MDXHEALTH, INC	171
MERCK CORPORATE HEADQUARTERS	171
METHYLGENE INC.	171
NEW ENGLAND BIOLABS	171
NOVARTIS INTERNATIONAL AG	171
ORION GENOMICS	172
PERKIN ELMER	172
PFIZER	172
PHARMACYCLICS, INC	172
PROGNOSDX HEALTH, INC.	172

<b>TOPIC</b>	<b>PAGE NO.</b>
RANA THERAPEUTICS INC.	172
REACTION BIOLOGY CORP.	173
RIBOMED BIOTECHNOLOGIES, INC.	173
SEQUENOM, INC.	173
SIGMA-ALDRICH	173
SIRTRIS	173
SYNDAX PHARMACEUTICALS, INC.	173
TAKEDA PHARMACEUTICALS U.S.A., INC.	174
THERMO FISHER SCIENTIFIC, INC.	174
VOLITIONRX	174
ZYMO RESEARCH CORPORATION	174



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES	15
TABLE 2 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES	16
TABLE 3 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITS FUNCTIONAL OUTCOMES	19
TABLE 4 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITS FUNCTIONAL OUTCOMES	22
TABLE 5 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITY AND BINDING PARTNERS	24
TABLE 6 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENT PATHOLOGIES	25
TABLE 7 PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOR EPIGENETIC RESEARCH (%)	28
TABLE 8 SELECT SUPPLIERS OF EPIGENETIC PRODUCTS	29
TABLE 9 PRODUCT CATEGORIES FOR HMT RESEARCH, COMPANIES MARKETING THE PRODUCTS AND AVERAGE PRICES	32
TABLE 10 GLOBAL MARKET FOR ANTIBODIES BY INDUSTRY SEGMENT, THROUGH 2016 (\$ BILLIONS)	33
TABLE 11 DISTRIBUTION OF VARIOUS APPLICATIONS FOR ANTIBODIES AS A RESEARCH TOOL (%)	33
TABLE 12 MAIN MARKET PARTICIPANTS IN RESEARCH ANTIBODY SEGMENT AND THEIR RELATIVE MARKET SHARES (%)	34
TABLE 13 SOURCES OF ANTIBODIES SUPPLY FOR RESEARCH AND THEIR PERCENTAGE ON THE MARKET	35
TABLE 14 PERCENTAGE USE OF SPECIFIC PROTEIN EXPRESSION TECHNIQUES (%)	37
TABLE 15 GLOBAL MARKET FOR PROTEIN CHROMATOGRAPHY, THROUGH 2016 (\$ MILLIONS)	38
TABLE 16 AVERAGE SPENDING PER SCIENTIST ON PURIFICATION AND SEPARATION PRODUCTS (%)	39
TABLE 17 GLOBAL MARKET SHARES OF RECOMBINANT ENZYME MARKET BY DIFFERENT TYPE OF ENZYME IN 2012 (%)	40
TABLE 18 GLOBAL RECOMBINANT ENZYME MARKET SHARES BY CUSTOMER (%)	41
TABLE 19 LIST OF LYSINE HISTONE METHYLTRANSFERASES (KMT) AND THEIR SUBSTRATES	41
TABLE 20 LIST OF LYSINE HISTONE DEMETHYLASES (KDM) AND THEIR SUBSTRATES	43
TABLE 21 LIST OF ARGININE HISTONE METHYLTRANSFERASES AND THEIR SUBSTRATES	44
TABLE 22 LIST OF INHIBITORS USED IN HISTONE METHYLTRANSFERASE RESEARCH AND PRODUCT DEVELOPMENT	46
TABLE 23 SUBSTRATES FOR HMTS FOR IN VITRO STUDIES AND PERCENTAGE OF THEIR USE (%)	47
TABLE 24 SELECT IN VITRO ASSAY AND COMMERCIAL KIT PROVIDERS	49
TABLE 25 LIST OF DIFFERENT ASSAY SET-UPS FOR HMT ACTIVITY MEASUREMENTS	51
TABLE 26 SURVEY OF SCIENTISTS' OPINIONS ABOUT EPIGENETICS SCREENING IN DRUG DISCOVERY (%)	57

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 27 STUDIES AND ASSAY DEVELOPMENT IN SPECIFIC DISEASE AREAS (%)	57
TABLE 28 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, THROUGH 2018 (\$ MILLIONS)	63
TABLE 29 ALTERED HISTONE MODIFICATIONS IN DIFFERENT PATHOLOGICAL CONDITIONS	65
TABLE 30 CURRENT APPROVED EPIGENETIC DRUGS ON THE MARKET	66
TABLE 31 SALES OF ZOLINZA, 2008-2010, (\$ MILLIONS)	67
TABLE 32 SALES OF ISTODAX, 2011 AND 2012 (\$ MILLIONS)	68
TABLE 33 SALES OF VIDAZA, 2010-2012 (\$ MILLIONS)	69
TABLE 34 SALES OF DACOGEN, 2009-2011 (\$ MILLIONS)	70
TABLE 35 EXAMPLES OF EPIGENETIC DRUG DISCOVERY PROGRAMS	71
TABLE 36 COMPANIES DEVELOPING THERAPEUTICS WITH HISTONE METHYLTRANSFERASE AS A DRUG DISCOVERY TARGET	82
TABLE 37 RECENT DRUG DISCOVERY DEVELOPMENTS FOR HISTONE METHYLTRANSFERASE INHIBITORS	84
TABLE 38 POTENTIAL MARKETS FOR HMTS DRUG DISCOVERY (\$ BILLIONS)	96
TABLE 39 DEALS IN EPIGENETICS MARKET IN THE LAST DECADE	96
TABLE 40 YEAR AND FUNDING AMOUNT FOR EPIGENETIC COMPANIES IN HMT DRUG DISCOVERY	102
TABLE 41 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, THROUGH 2018 (\$ MILLIONS)	103
TABLE 42 POTENTIAL EPIGENETICS TARGETS FOR DRUG DISCOVERY: EPIGENETIC ENZYMES CLASSES IMPORTANT IN COVALENT MODIFICATION OF DNA OR HISTONES	103
TABLE 43 RELATIONSHIP BETWEEN DEMETHYLASES, METHYLTRANSFERASES AND THEIR RESPECTIVE HISTONE METHYLATION SITES	108
TABLE 44 RELATIONSHIP BETWEEN HISTONE METHYLATION, METHYL READERS AND THEIR FUNCTIONS	109
TABLE 45 NUMBER OF PUBMED PUBLICATIONS ON BIOMARKERS USING DIFFERENT EPIGENETIC MECHANISMS, 2012	114
TABLE 46 DNA METHYLATION EVENTS AND THEIR RELATION TO DIFFERENT PATHOLOGIES	115
TABLE 47 NUMBER OF PUBLICATIONS IN HISTONE METHYLATION AREA BASED ON DIFFERENT SEARCH CRITERIA	118
TABLE 48 RELATIONSHIP BETWEEN HISTONE METHYLATION AND CANCER PROGNOSIS	119
TABLE 49 DIFFERENT HISTONE METHYLTRANSFERASES AND THEIR ASSOCIATION TO CANCER DEVELOPMENT	124
TABLE 50 DEMETHYLASES AND THEIR ASSOCIATIONS WITH CANCER DEVELOPMENT	127
TABLE 51 GLOBAL BIOMARKERS MARKET, THROUGH 2015 (\$ BILLIONS)	129
TABLE 52 SELECT EPIGENETICS DIAGNOSTICS COMPANIES	129
TABLE 53 EXAMPLES OF AVERAGE REVENUES IN EPIGENETIC DIAGNOSTICS COMPANIES	141
TABLE 54 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	143
TABLE 55 DIAGNOSTICS MARKET VALUES IN ONCOLOGY SECTOR, 2013 (\$ BILLIONS)	144

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 56 WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH IN HISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS (NO. OF PATENTS)	146
TABLE 57 WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENT APPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDING TO ASSIGNEE	148
TABLE 58 NUMBER OF PUBLICATIONS USING HISTONE METHYLTRANSFERASE AS SEARCH, 2000-2012	150
TABLE 59 DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS IN EPIGENETIC SPACE (%)	151
TABLE 60 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	152
TABLE 61 EXAMPLES OF MARKET PARTICIPANTS IN HISTONE METHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS	153

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 SCHEMATIC PRESENTATION OF METHYLATION REACTION	17
FIGURE 2 SCHEMATIC REPRESENTATION OF HMTS ASSAY DEVELOPMENT	49
FIGURE 3 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, 2011-2018 (\$ MILLIONS)	63
FIGURE 4 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, 2011-2018 (\$ MILLIONS)	103
FIGURE 5 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, 2011-2018 (\$ MILLIONS)	143
FIGURE 6 NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONE METHYLTRANSFERASE AS SEARCH	150
FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)	153